#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	14884	16S	1529	1529	99.93	16S.l6.c30.ctg.1	2071	709.9	0	.	n	.	0	A198G	SNP	198	198	A	424	424	G	825	G,A,T	445,346,1	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	14884	16S	1529	1529	99.93	16S.l6.c30.ctg.1	2071	709.9	1	SNP	n	C1184T	0	.	.	1184	1184	C	1410	1410	C	873	C	841	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	28280	23S	2890	2890	99.9	23S.l6.c4.ctg.1	3600	779.6	0	.	n	.	0	T695C	SNP	695	695	T	1030	1030	C	827	C,G	796,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	28280	23S	2890	2890	99.9	23S.l6.c4.ctg.1	3600	779.6	0	.	n	.	0	G1337A	SNP	1337	1337	G	1672	1672	A	968	A,G	934,2	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	28280	23S	2890	2890	99.9	23S.l6.c4.ctg.1	3600	779.6	0	.	n	.	0	T1971C	SNP	1971	1971	T	2306	2306	C	923	C	884	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	28280	23S	2890	2890	99.9	23S.l6.c4.ctg.1	3600	779.6	1	SNP	n	A2045G	0	.	.	2045	2045	A	2380	2380	A	905	A	874	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	28280	23S	2890	2890	99.9	23S.l6.c4.ctg.1	3600	779.6	1	SNP	n	C2597T	0	.	.	2597	2597	C	2932	2932	C	850	C	828	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_P_01364c	folP.WHO_P_01364c	1	1	27	1772	folP	852	852	100.0	folP.l6.c17.ctg.1	1374	127.5	1	SNP	p	R228S	1	.	.	682	684	AGC	948	950	AGC	162;164;166	A;G;C	154;156;157	folP.WHO_P_01364c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	4958	gyrA	2751	2751	100.0	gyrA.l15.c4.ctg.1	3525	139.7	1	SNP	p	S91F	0	.	.	271	273	TCC	578	580	TCC	170;169;171	T;C;C	162;164;163	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	4958	gyrA	2751	2751	100.0	gyrA.l15.c4.ctg.1	3525	139.7	1	SNP	p	D95G	0	.	.	283	285	GAC	590	592	GAC	155;155;155	G,C;A;C	148,1;146;148	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	4958	gyrA	2751	2751	100.0	gyrA.l15.c4.ctg.1	3525	139.7	1	SNP	p	D95N	0	.	.	283	285	GAC	590	592	GAC	155;155;155	G,C;A;C	148,1;146;148	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_O_01438	mtrR.WHO_O_01438	1	1	539	1606	mtrR	633	633	99.21	mtrR.l15.c30.ctg.1	1423	112.1	0	.	p	.	0	A39T	NONSYN	115	117	GCC	514	516	ACC	199;198;197	A,C;C;C	188,1;191;188	.	.
mtrR.WHO_O_01438	mtrR.WHO_O_01438	1	1	539	1606	mtrR	633	633	99.21	mtrR.l15.c30.ctg.1	1423	112.1	0	.	p	.	0	R44H	NONSYN	130	132	CGC	529	531	CAC	182;181;183	C;A;C	174;171;173	.	.
mtrR.WHO_O_01438	mtrR.WHO_O_01438	1	1	539	1606	mtrR	633	633	99.21	mtrR.l15.c30.ctg.1	1423	112.1	0	.	p	.	0	Y105H	NONSYN	313	315	TAC	712	714	CAC	184;183;183	C;A;C	176;175;174	.	.
mtrR.WHO_O_01438	mtrR.WHO_O_01438	1	1	539	1606	mtrR	633	633	99.21	mtrR.l15.c30.ctg.1	1423	112.1	1	SNP	p	G45D	0	.	.	133	135	GGC	532	534	GGC	183;180;181	G;G;C	175;170;173	mtrR.WHO_O_01438:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	19	1014	mtrR_promoter	250	250	100.0	mtrR_promoter.l6.c30.ctg.1	1065	94.1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	4624	parC	2304	2304	100.0	parC.l6.c30.ctg.1	2937	155.5	1	SNP	p	D86N	0	.	.	256	258	GAC	688	690	GAC	186;188;188	G;A;C	181;180;183	parC.WHO_P_00203c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	4624	parC	2304	2304	100.0	parC.l6.c30.ctg.1	2937	155.5	1	SNP	p	S87W	0	.	.	259	261	AGT	691	693	AGT	190;188;189	A,C;G;T	183,1;181;179	parC.WHO_P_00203c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	4624	parC	2304	2304	100.0	parC.l6.c30.ctg.1	2937	155.5	1	SNP	p	S87I	0	.	.	259	261	AGT	691	693	AGT	190;188;189	A,C;G;T	183,1;181;179	parC.WHO_P_00203c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	4624	parC	2304	2304	100.0	parC.l6.c30.ctg.1	2937	155.5	1	SNP	p	S87R	0	.	.	259	261	AGT	691	693	AGT	190;188;189	A,C;G;T	183,1;181;179	parC.WHO_P_00203c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	4624	parC	2304	2304	100.0	parC.l6.c30.ctg.1	2937	155.5	1	SNP	p	S88P	0	.	.	262	264	TCC	694	696	TCC	188;188;184	T;C;C	180;180;178	parC.WHO_P_00203c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	3954	parE	1986	1986	100.0	parE.l15.c30.ctg.1	2772	141.9	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1645	1647	GGC	165;163;160	G;G;C	160;158;152	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.2.001	penA.2.001	1	1	27	3782	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2413	155.3	1	SNP	p	A311V	0	.	.	931	933	GCA	1293	1295	GCA	213;217;216	G,T;C;A	203,1;204;207	penA.2.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3782	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2413	155.3	1	SNP	p	I312M	0	.	.	934	936	ATC	1296	1298	ATC	217;215;215	A;T;C	206;207;209	penA.2.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3782	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2413	155.3	1	SNP	p	V316T	0	.	.	946	948	GTG	1308	1310	GTG	205;198;198	G;T;G	199;191;189	penA.2.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3782	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2413	155.3	1	SNP	p	V316P	0	.	.	946	948	GTG	1308	1310	GTG	205;198;198	G;T;G	199;191;189	penA.2.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3782	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2413	155.3	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1812	1814	ACC	151;152;149	A;C;C	141;149;143	penA.2.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3782	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2413	155.3	1	SNP	p	A502V	0	.	.	1504	1506	GCG	1866	1868	GCG	134;135;137	G;C,G;G	125;117,1;123	penA.2.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3782	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2413	155.3	1	SNP	p	A502P	0	.	.	1504	1506	GCG	1866	1868	GCG	134;135;137	G;C,G;G	125;117,1;123	penA.2.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3782	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2413	155.3	1	SNP	p	G543S	0	.	.	1627	1629	GGC	1989	1991	GGC	145;143;142	G;G;C	142;140;140	penA.2.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3782	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2413	155.3	1	SNP	p	G546S	0	.	.	1636	1638	GGC	1998	2000	GGC	137;133;133	G;G;C	131;128;124	penA.2.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3782	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2413	155.3	1	SNP	p	P552S	0	.	.	1654	1656	CCG	2016	2018	CCG	95;98;96	C,G;C,G;G,C	86,2;89,1;87,1	penA.2.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	5566	ponA	2397	2397	100.0	ponA.l15.c4.ctg.1	3080	179.3	1	SNP	p	L421P	1	.	.	1261	1263	CCG	1660	1662	CCG	183;181;181	C;C;G	166;175;169	ponA.WHO_G_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2432	porA	1146	1146	99.83	porA.l6.c17.ctg.1	1778	135.1	0	.	p	.	0	M83fs	FSHIFT	247	247	A	522	522	C	159	C	144	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2596	porB1b	1041	1041	96.09	porB1b.l15.c30.ctg.1	1494	170.9	0	.	p	.	0	T18M	NONSYN	52	54	ACG	359	361	ATG	190;188;187	A;T;G	186;184;184	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2596	porB1b	1041	1041	96.09	porB1b.l15.c30.ctg.1	1494	170.9	0	.	p	.	0	E41K	NONSYN	121	123	GAA	428	430	AAA	175;174;177	A;A;A	165;166;169	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2596	porB1b	1041	1041	96.09	porB1b.l15.c30.ctg.1	1494	170.9	0	.	p	.	0	E48G	NONSYN	142	144	GAA	449	451	GGA	194;195;196	G;G;A	190;189;187	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2596	porB1b	1041	1041	96.09	porB1b.l15.c30.ctg.1	1494	170.9	0	.	p	.	0	V75I	NONSYN	223	225	GTT	530	532	ATT	207;206;208	A;T,C;T	198;197,1;201	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2596	porB1b	1041	1041	96.09	porB1b.l15.c30.ctg.1	1494	170.9	0	.	p	.	0	T87A	NONSYN	259	261	ACT	566	568	GCT	194;194;197	G;C;T	183;184;188	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2596	porB1b	1041	1041	96.09	porB1b.l15.c30.ctg.1	1494	170.9	0	.	p	.	0	T89S	NONSYN	265	267	ACC	572	574	AGC	197;196;195	A,G;G;C	191,1;188;189	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2596	porB1b	1041	1041	96.09	porB1b.l15.c30.ctg.1	1494	170.9	0	.	p	.	0	V98I	NONSYN	292	294	GTC	599	601	ATC	197;198;199	A;T;C	188;188;185	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2596	porB1b	1041	1041	96.09	porB1b.l15.c30.ctg.1	1494	170.9	0	.	p	.	0	.	MULTIPLE	358	359	AA	664	665	CG	183;178	C;G	170;162	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2596	porB1b	1041	1041	96.09	porB1b.l15.c30.ctg.1	1494	170.9	0	.	p	.	0	.	MULTIPLE	361	362	GA	667	669	CAG	178;177;177	C,A;A;G	165,1;164;163	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2596	porB1b	1041	1041	96.09	porB1b.l15.c30.ctg.1	1494	170.9	0	.	p	.	0	N122K	NONSYN	364	366	AAC	671	673	AAA	179;182;182	A,C;A;A	165,1;175;173	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2596	porB1b	1041	1041	96.09	porB1b.l15.c30.ctg.1	1494	170.9	0	.	p	.	0	F131Y	NONSYN	391	393	TTT	698	700	TAT	204;203;203	T;A,T;T	191;191,1;191	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2596	porB1b	1041	1041	96.09	porB1b.l15.c30.ctg.1	1494	170.9	0	.	p	.	0	N134E	NONSYN	400	402	AAT	707	709	GAG	193;196;200	G,A;A;G,T	178,1;185;187,1	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2596	porB1b	1041	1041	96.09	porB1b.l15.c30.ctg.1	1494	170.9	0	.	p	.	0	V135F	NONSYN	403	405	GTG	710	712	TTT	198;198;196	T,G,C;T;T,G	179,1,1;183;184,1	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2596	porB1b	1041	1041	96.09	porB1b.l15.c30.ctg.1	1494	170.9	0	.	p	.	0	G140K	NONSYN	418	420	GGA	725	727	AAA	189;192;194	A,G;A,G;A	179,1;183,1;184	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2596	porB1b	1041	1041	96.09	porB1b.l15.c30.ctg.1	1494	170.9	0	.	p	.	0	K143E	NONSYN	427	429	AAA	734	736	GAA	186;179;184	G,A;A;A	174,1;170;171	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2596	porB1b	1041	1041	96.09	porB1b.l15.c30.ctg.1	1494	170.9	0	.	p	.	0	V151A	NONSYN	451	453	GTA	758	760	GCA	207;203;205	G,T;C,T;A	198,1;193,1;194	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2596	porB1b	1041	1041	96.09	porB1b.l15.c30.ctg.1	1494	170.9	0	.	p	.	0	T213S	NONSYN	637	639	ACA	944	946	TCA	204;205;207	T;C;A	195;193;197	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2596	porB1b	1041	1041	96.09	porB1b.l15.c30.ctg.1	1494	170.9	0	.	p	.	0	G253Q	NONSYN	757	759	GGA	1064	1066	CAA	191;189;191	C;A;A	189;187;188	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2596	porB1b	1041	1041	96.09	porB1b.l15.c30.ctg.1	1494	170.9	0	.	p	.	0	.	INDELS	760	762	ACA	1068	1072	ATCAA	195;192;190;188;190	A;T;C;A;A	192;187;187;187;189	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2596	porB1b	1041	1041	96.09	porB1b.l15.c30.ctg.1	1494	170.9	0	.	p	.	0	.	INDELS	763	764	TG	1075	1077	AGT	191;191;189	A;G;T	191;190;186	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2596	porB1b	1041	1041	96.09	porB1b.l15.c30.ctg.1	1494	170.9	0	.	p	.	0	A257D	NONSYN	769	771	GCT	1082	1084	GAT	193;193;196	G;A;T	190;192;196	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2596	porB1b	1041	1041	96.09	porB1b.l15.c30.ctg.1	1494	170.9	0	.	p	.	0	T269S	NONSYN	805	807	ACC	1118	1120	AGC	218;217;216	A;G;C	210;210;209	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2596	porB1b	1041	1041	96.09	porB1b.l15.c30.ctg.1	1494	170.9	0	.	p	.	0	D293S	NONSYN	877	879	GAT	1190	1192	AGT	219;220;215	A,G;G,A;T	211,1;212,1;207	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2596	porB1b	1041	1041	96.09	porB1b.l15.c30.ctg.1	1494	170.9	0	.	p	.	0	N295D	NONSYN	883	885	AAC	1196	1198	GAC	224;225;226	G,A;A;C	219,1;218;222	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2596	porB1b	1041	1041	96.09	porB1b.l15.c30.ctg.1	1494	170.9	0	.	p	.	0	H296Y	NONSYN	886	888	CAC	1199	1201	TAC	233;235;239	T,C;A;C	227,1;226;233	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2596	porB1b	1041	1041	96.09	porB1b.l15.c30.ctg.1	1494	170.9	1	SNP	p	G120K	1	.	.	358	360	AAG	664	666	CGG	183;178;176	C;G;G	170;162;167	porB1b.WHO_M_02204c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2596	porB1b	1041	1041	96.09	porB1b.l15.c30.ctg.1	1494	170.9	1	SNP	p	D121N	0	.	.	361	363	GAC	667	670	CGC	178;177;176	C,A;G;C	165,1;163;163	porB1b.WHO_M_02204c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2596	porB1b	1041	1041	96.09	porB1b.l15.c30.ctg.1	1494	170.9	1	SNP	p	A121D	1	.	.	361	363	GAC	667	670	CGC	178;177;176	C,A;G;C	165,1;163;163	porB1b.WHO_M_02204c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	9844	rpoB	4179	4179	100.0	rpoB.l6.c4.ctg.1	4896	199.5	1	SNP	p	H553N	1	.	.	1657	1659	AAT	2021	2023	AAT	226;224;226	A,C;A;T	216,1;217;217	rpoB.WHO_M_02157:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	1174	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1185	98.2	1	SNP	p	V57M	1	.	.	169	171	ATG	559	561	ATG	235;233;229	A;T;G	226;225;221	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
